Ovarian cancer is often advanced by the time it is diagnosed. That's why it's important to choose a treatment center with the high volume, experience, and advanced care to ensure the best possible treatment outcome.
Penn Medicine is nationally recognized for its ovarian cancer care, offering more possibilities for treatment and cutting-edge clinical trials that draw patients from all over the world.
We see over 200 new ovarian cancer patients a year
The Abramson Cancer Center is a high-volume cancer center, meaning that we treat a large number of people with cancer. Studies show that treatment at a high-volume cancer center increases the odds of survival.
Our ovarian cancer care is collaborative
We have more full-time board certified gynecologic oncologists than any other hospital in the Philadelphia region. Our entire team, including medical oncologists, pathologists, surgeons and radiation specialists, meets weekly to discuss joint treatment plans for each of our unique patients. However, cancer and its treatment can affect the whole body. That's why we partner closely with specialists throughout the Penn system: This collaborative model lets us take on a greater complexity of care.
We look at ovarian cancer care from all angles
The Ovarian Cancer Translational Center of Excellence (TCE) supports innovation in ovarian cancer treatment by bridging the gap between Penn's groundbreaking scientific discoveries and the creation of lifesaving new therapies. This transformative project collects tumor tissue from a range of patients to study how ovarian cancer evolves. This data is then used to create therapies that aren't available anywhere else, which are then made available to our patients.
We have one of the largest ovarian cancer laboratories in the country
Ovarian cancer is a top clinical and research priority at Penn Medicine. Our lab capabilities allow us to analyze each unique cancer and develop precision treatments for our patients. This work helps us develop and test new therapies that can benefit all ovarian cancer patients in the future.
We are home to the only SPORE-funded ovarian cancer research program in the region
We are the only National Cancer Institute-sponsored Specialized Program of Research Excellence (SPORE) in ovarian cancer in the region, and one of only a few nationally.
SPORE grants are highly competitive and help research findings move more quickly (translate) from the lab into clinical practice. This ability to translate findings is a cornerstone of our Gynecologic Oncology Program.
Many of our expert physicians are also research leaders, meaning we have a unique perspective in compassionately diagnosing and treating your cancer, while continually working toward a cure.